Skip to main content

Table 1 Summary of AEs, SAEs, AESIs, and ADRs reported in patients receiving R-chemo

From: Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

Baseline characteristics AE (any grade), n (%) AE (grade 3–4), n (%) SAE, n (%) AESI, n (%) ADR, n (%)
Total (n = 279) 267(95.7) 147(52.7) 47(16.8) 46 (16.5) 226 (81.0)
Age, y 19–60 (n = 160) 206 (95.8) 103 (47.9) 30 (14.0) 32 (14.9) 172 (80.0)
61–80 (n = 109) 22 (95.7) 16 (69.6) 7(30.4) 6 (26.1) 21(91.3)
≤18 to >80 (n = 10) 42 (95.5) 30 (68.2) 11(25.0) 9 (20.5) 36 (81.8)
History of diseases Heart diseases (n = 23) 10 (100.0) 5 (50.0) 3 (30.0) 2 (20.0) 10 (100.0)
Liver diseases (n = 44) 152 (95.0) 76 (47.5) 22 (13.8) 22 (13.8) 126 (78.8)
No heart or liver diseases (n = 215) 105 (96.3) 66 (60.6) 22 (20.2) 22 (20.2) 90 (82.6)
  1. ADR adverse drug reaction, AE adverse event, AESI adverse event of special interest, chemo chemotherapy, SAE severe adverse event, R rituximab, y year